14-3-3ζ蛋白表达与胃癌相关性的Meta分析  

The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer:A Meta-Analysis

作　　者：张雅婷[1] 李沛 贺轶迪 李易桐 李玉民[1] ZHANG Ya-ting;LI Pei;HE Yi-di;LI Yi-tong;LI Yu-min(Key Laboratory of Digestive System Tumors of Gansu Province,The Second Clinical Medical College of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]甘肃省消化肿瘤实验室、兰州大学第二临床医学院,兰州730000

出　　处：《循证医学》2020年第2期89-95,102,共8页The Journal of Evidence-Based Medicine

基　　金：国家自然科学基金资助项目(31770537、81572437);甘肃省科技计划资助项目(18YF1WA113);兰州大学第二医院“萃英学子科研培育”计划资助项目。

摘　　要：目的评价14-3-3ζ蛋白的表达与胃癌的相关性。方法计算机检索中国期刊全文数据库、维普中文科技期刊数据库、中国生物医学文献数据库、万方数据知识服务平台、PubMed、Web of Science核心合集、Cochrane图书馆和EMBASE数据库,搜集国内外公开发表关于14-3-3ζ蛋白的表达与胃癌相关性的研究,检索时限至2019年11月14日。筛选文献、提取资料和评价纳入研究的偏倚风险后,采用RevMan 5.3.5软件进行Meta分析。结果共纳入6篇文献,共计671例胃癌组织,其中14-3-3ζ蛋白高表达的胃癌组织为414例,低表达257例。Meta分析结果显示:胃癌组织中14-3-3ζ蛋白多呈高表达[比值比=4.94,95%可信区间(1.29,18.82),P=0.02],高表达多见于肿瘤临床分期为Ⅲ~Ⅳ期的胃癌患者[比值比=0.34,95%可信区间(0.12,0.92),P=0.03];但与年龄[比值比=0.87,95%可信区间(0.59,1.28),P=0.48]、性别[比值比=1.11,95%可信区间(0.72,1.69),P=0.64]及肿瘤大小[比值比=0.74,95%可信区间(0.30,1.84),P=0.02]无相关性。在生存方面,14-3-3ζ蛋白低表达组胃癌患者的1年[风险比=18.25,95%可信区间(6.53,51.04),P<0.000 01]、2年[风险比=24.37,95%可信区间(9.25,64.25),P<0.000 01]、3年[风险比=20.90,95%可信区间(7.01,62.31),P<0.000 01]、5年[风险比=19.03,95%可信区间(7.02,51.62),P<0.000 01]总体生存率均明显高于高表达组。结论 14-3-3ζ蛋白表达与患者的临床分期及预后显著相关。Objective To evaluate the correlation between the expression web of Science of 14-3-3ζprotein and gastric cancer.Methods CNKI,VIP,CBM,WanFang Data,PubMed,Cochrane Library and EMBASE,were searched to identify studies on 14-3-3ζexpression for gastric cancer before November 14th,2019.Meta-analysis was performed using RevMan 5.3.5 software after screening the literature,extracting data,and evaluating the risk of bias in the included studies.Results A total of 671 cases of gastric cancer were included in the cross-sectional study.Among them,14-3-3ζprotein was high expressed in 414 cases and low expressed in 257.Meta-analysis shows that 14-3-3ζprotein was high expressed in gastric cancer tissues(OR=4.94,95%CI 1.29 to 18.82,P=0.02),and its high expression was more common in tumors with clinical stageⅢ~Ⅳgastric cancer patients(OR=0.34,95%CI 0.12 to 0.92,P=0.03);but with age(OR=0.87,95%CI 0.59 to 1.28,P=0.48),gender(OR=1.11,95%CI 0.72 to 1.69,P=0.64)as well as tumor size(0.74,95%CI 0.30 to 1.84,P=0.02)had no significant relationship.1-year[HR=18.25,95%CI(6.53,51.04),P<0.00001],2-year(HR=24.37,95%CI 9.25 to 64.25,P<0.00001),3-year(HR=20.90,95%CI 7.01 to 62.31,P<0.00001)and 5-year overall survival rate(HR=19.03,95%CI 7.02 to 51.62,P<0.00001)of 14-3-3ζprotein low expression group were significantly higher than high expression group.Conclusion The expression of 14-3-3ζprotein is markedly correlated with clinical stage and the prognosis of gastric cancer.

关 键 词：14-3-3ζ蛋白 胃癌 临床分期 META分析 

分 类 号：R735.2[医药卫生—肿瘤]